Wednesday, 1 January 2014

Gardasil Vaccine

Gardasil, the HPV vaccine is used in the childhood vaccination programme and is recommended for girls 12 to 13 years old to protect against certain viruses which may lead to cervical cancer in later years.

According to NHS Choices more than one in ten girls who have the Gardasil HPV vaccine will experience side effects but most of these will not be serious. Fewer than one in 10,000 girls may experience restriction of the airways and difficult breathing. Other side effects are of unknown frequency because the information has to come from people reporting the side effects, rather than clinical trials. However, some of the comments on NHS Choices about the side effects are very serious.

The Tokyo Times has reported that the Japanese government has withdrawn Gardasil from the market
"Japanese health officials have recorded nearly 2,000 adverse reactions – hundreds of them serious," reported Judicial Watch, the Washington-based corruption watchdog that has been monitoring the effects – and health costs – of the drug’s use in the United States for years.
"The alarming reports have led Japan’s government to take action, suspending recommendation for the controversial vaccine which is billed as a miracle shot that can prevent certain strains of cervical cancer caused by Human Papillomavirus (HPV)."
"The U.S. government has taken the opposite approach amid equally alarming cases of serious side effects. Not only does the Obama administration continue recommending the vaccine (Gardasil), it spends large sums of taxpayer dollars promoting it and works hard to keep details involving its dangers secret."
The side effects of using Gardasil include seizures, brain damage, blindness, paralysis, speech problems, pancreatitis and short-term memory loss, while other patients have died after taking the vaccine. Gardasil is given to little girls and costs around $600 per patient.
The organization confirmed that in Japan, the Ministry of Health, Labor and Welfare warned local governments that the HPV vaccine should not be recommended amid safety concerns.
Research is still ongoing because it is not yet clear how long the vaccine provides protection for, and if booster doses are required.
According to Eurosurveillance: "The uptake rate for completed courses of HPV immunisation in the routine cohort in Scotland (91% in the first year of implementation) is amongst the highest reported in the world" They go on to say:
Further analyses and discussion on HPV uptake rates within Scotland are in preparation. The HPV immunisation campaign continues in Scotland for girls aged 12–13 years. Our current surveillance work focuses on identifying the effects of vaccination on HPV infections identified through attendance at first cervical screening appointment. In Scotland, cervical screening currently begins at age 20 years, and in 2012 we estimate around 70% of girls attending screening at age 20 will have received three doses of HPV vaccine.
 So this is an experiment in progress.

Information about harmful vaccinations HERE

No comments:

Post a Comment